23G transconjunctival sutureless vitrectomy safe & effective

Article

Twenty-three gauge transconjunctival sutureless vitrectomy is an effective surgical technique for the management of vitreoretinal diseases.

Twenty-three gauge transconjunctival sutureless vitrectomy is an effective surgical technique for the management of vitreoretinal diseases, according to a study published in the February issue of Retina.

Asheesh Tewari and colleagues from the Kresge Eye Institute, Wayne State University School of Medicine, Michigan, US conducted a retrospective chart review of 81 consecutive 23-gauge vitrectomy cases carried out by a single surgeon for various posterior segment conditions.

Mean follow-up was 6.5 months (range: three to nine months). Mean preoperative visual acuity (VA) was 20/150 and final VA was 20/70 (p<0.0001). Mean intraocular pressure (IOP) on the first day postoperatively was 14 mmHg (range: 6 - 28 mmHg). There was a single case of intraoperative retinal tear that required treatment with cryotherapy and 20 eyes of 48 phakic eyes (42%) had worsening cataracts during the postoperative period. There were no recorded cases of endophthalmitis or retinal detachment.

It was the conclusion of the researchers that 23-gauge transconjunctival sutureless vitrectomy is both safe and effective.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.